Skip to main content

Neoleukin Therapeutics, Inc. (NLTX)

NASDAQ: NLTX · Delayed Price · USD
7.68 0.15 (1.99%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap325.82M
Revenue (ttm)n/a
Net Income (ttm)-44.97M
Shares Out42.43M
EPS (ttm)-0.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume50,305
Open7.57
Previous Close7.53
Day's Range7.42 - 7.70
52-Week Range5.95 - 17.95
Beta0.96
AnalystsStrong Buy
Price Target21.83 (+184.2%)
Est. Earnings DateNov 4, 2021

About NLTX

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neole...

IndustryBiotechnology
Founded2003
Employees92
Stock ExchangeNASDAQ
Ticker SymbolNLTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for NLTX stock is "Strong Buy." The 12-month stock price forecast is 21.83, which is an increase of 184.24% from the latest price.

Price Target
$21.83
(184.24% upside)
Analyst Consensus: Strong Buy

News

Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...

2 weeks ago - GlobeNewsWire

Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference

SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein the...

3 months ago - GlobeNewsWire

Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update

- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 -

4 months ago - GlobeNewsWire

Ne­oleuk­in's IL-2 Agonist Candidate Cleared To Start Phase 1 Trial In Solid Tumors

The FDA has removed the clinical hold related to Neoleukin Therapeutics Inc (NASDAQ: NLTX) investigational new drug application, to begin a Phase 1 program of its cancer immunotherapeutic candidate, NL-...

4 months ago - Benzinga

Neoleukin Therapeutics Announces Year End 2020 Financial Results

- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 -

5 months ago - GlobeNewsWire

Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...

6 months ago - GlobeNewsWire

Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

7 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX

New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su c...

7 months ago - Newsfile Corp

SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) -  Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal se...

7 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX

New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su c...

8 months ago - Newsfile Corp

Why Neoleukin Therapeutics Stock Is Down Today

The company is experiencing regulatory headwinds.

8 months ago - The Motley Fool

Aquinox (NLTX) Moves to Buy: Rationale Behind the Upgrade

Aquinox (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

8 months ago - Zacks Investment Research

Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201

SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

8 months ago - GlobeNewsWire

Neoleukin: New Phase 1 Initiation, Strong Managerial Expertise, And Promising Technology

Neoleukin Therapeutics is a biopharmaceutical company that creates next-gen immunotherapies targeting cancer, inflammation, and autoimmunity. Neoleukin's unique value-add is its specialization in novel-...

9 months ago - Seeking Alpha

Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immuno...

SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

9 months ago - GlobeNewsWire

Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

10 months ago - GlobeNewsWire

Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

10 months ago - GlobeNewsWire

Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer's 35th...

- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation -

10 months ago - GlobeNewsWire

Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update

- NL-201 IND submission anticipated by year end 2020 -

10 months ago - GlobeNewsWire

Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vi...

- I ntranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection –

10 months ago - GlobeNewsWire

Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel

SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

11 months ago - GlobeNewsWire

Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer’s 35th...

SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...

11 months ago - GlobeNewsWire

Top Pharmaceutical Stocks for Q4 2020

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

1 year ago - Investopedia

Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...

1 year ago - GlobeNewsWire

Neoleukin (NLTX) Upgraded to Buy: What Does It Mean for the Stock?

Neoleukin (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research